| Cancer immunoprevention. | |
| | |
MedLine Citation:
|
PMID: 16555976 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Immunoprevention is a fresh approach to cancer prevention based on the stimulation of the immune system before tumor onset. Immunoprevention was effective in various models of carcinogen-induced or autochthonous tumor progression. Vaccines made of cells or DNA plasmids combined with appropriate adjuvants completely blocked mammary carcinogenesis in HER-2/neu transgenic mice. At variance with cancer immunotherapy, the mediators of immunoprevention are antibodies and T-cell-derived cytokines, rather than cytotoxic T-cells. Immunopreventive approaches and chemoprevention with tamoxifen or cyclooxygenase-2 inhibitors can be combined advantageously. The success obtained in preclinical studies suggests that cancer immunoprevention should progress to clinical testing. |
| | |
Authors:
|
Pier-Luigi Lollini; Carla De Giovanni; Tania Pannellini; Federica Cavallo; Guido Forni; Patrizia Nanni |
Related Documents
:
|
21462876 - Gaining a better understanding of the support function of oncology nurse navigators fro... 17309326 - Immunotherapy of melanoma: a critical review of current concepts and future strategies. 23055216 - Photodynamic therapy for pancreatic and biliary tract cancer: the united kingdom experi... 20416856 - Self/not self, innate immunity, danger, cancer potential. 1339906 - Rectal cancer: 10 years experience at aub-mc. 10946166 - Opioid responsiveness-primary diagnosis relationship in advanced cancer patients follow... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Future oncology (London, England) Volume: 1 ISSN: 1479-6694 ISO Abbreviation: - Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2006-03-24 Completed Date: 2006-05-04 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 101256629 Medline TA: Future Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 57-66 Citation Subset: IM |
Affiliation:
|
Cancer Research Section, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I-40126 Bologna, Italy. pierluigi.lollini@unibo.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / therapeutic use Anticarcinogenic Agents / therapeutic use Cancer Vaccines / immunology Humans Immune System / physiology Interleukin-12 / genetics Mice Mice, Transgenic Neoplasms / immunology*, prevention & control* Precancerous Conditions / immunology, prevention & control Receptor, erbB-2 / immunology*, physiology T-Lymphocytes, Cytotoxic / immunology Vaccines, DNA / immunology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Anticarcinogenic Agents; 0/Cancer Vaccines; 0/Vaccines, DNA; 187348-17-0/Interleukin-12; EC 2.7.10.1/Receptor, erbB-2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Biomarkers of genetic susceptibility to cancer: applications to epidemiological studies.
Next Document: Role of IkappaB kinase in tumorigenesis.